Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab

被引：0
|
作者：
Khan, M. [1 ]
Heetun, Z. [1 ]
Moloney, J. [1 ]
Courtney, G. [1 ]
Aftab, A. R. [1 ]
机构：
[1] St Lukes Hosp, Kilkenny, Kilkenny, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5 (14S114)
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [41] Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease
    Merras-Salmio, Laura
    Kolho, Kaija-Leena
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (02): : 272 - 278
  • [42] Stability of serum concentrations of infliximab and adalimumab across pregnancy in inflammatory bowel disease
    Flanagan, E.
    Gibson, P.
    Ross, A.
    Rosella, O.
    Bell, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 152 - 153
  • [43] THE CLINICAL AND FINANCIAL IMPACT OF MEASURING INFLIXIMAB LEVELS AND ANTIBODIES TO INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS
    O'Reilly, S.
    Keegan, D.
    Byrne, K.
    Sheridan, J.
    Mulcahy, H. E.
    Doherty, G. A.
    Cullen, G.
    GUT, 2017, 66 : A2 - A3
  • [44] Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Van Assche, Gert
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2019, 68 (06): : 847 - 853
  • [45] Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease
    Singh, Namita
    Rosenthal, Casey J.
    Melmed, Gil Y.
    Mirocha, James
    Farrior, Sharmayne
    Callejas, Silvia
    Tripuraneni, Bhavna
    Rabizadeh, Shervin
    Dubinsky, Marla C.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1708 - 1713
  • [46] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [47] A Comparison of Combination Therapy With Infliximab or Adalimumab and an Immunosuppressive Agent Versus Monotherapy in Patients With Inflammatory Bowel Disease
    Barnes, Edward L.
    Lucci, Matthew B.
    Collins, Emily
    Cao, Bonnie
    Carrellas, Madeline
    Crowell, Anne Marie
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2015, 148 (04) : S268 - S268
  • [48] Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease
    Holmstrom, Rikke B.
    Mogensen, Ditte V.
    Brynskov, Jorn
    Ainsworth, Mark A.
    Nersting, Jacob
    Schmiegelow, Kjeld
    Steenholdt, Casper
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (06) : 1583 - 1591
  • [49] Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease
    Rikke B. Holmstrøm
    Ditte V. Mogensen
    Jørn Brynskov
    Mark A. Ainsworth
    Jacob Nersting
    Kjeld Schmiegelow
    Casper Steenholdt
    Digestive Diseases and Sciences, 2018, 63 : 1583 - 1591
  • [50] Rapid desensitization for the management of hypersensitivity reaction to biologicals-Infliximab and adalimumab in inflammatory bowel disease patients
    Novotna, B.
    Prochazkova, L.
    Zboril, V
    Prokopova, L.
    Smerkova, H.
    ALLERGY, 2017, 72 : 223 - 224
12345